title: Effects of hyperosmolarity on the Na+ -myo-inositol cotransporter SMIT2 stably transfected in the Madin-Darby canine kidney cell line.
abstract: Myo-inositol (MI) is a compatible osmolyte used by cells to compensate for changes in the osmolarity of their surrounding milieu. In kidney, the basolateral Na(+)-MI cotransporter (SMIT1) and apical SMIT2 proteins are homologous cotransporters responsible for cellular uptake of MI. It has been shown in the Madin-Darby canine kidney (MDCK) cell line that SMIT1 expression was under the control of the tonicity-sensitive transcription factor, tonicity-responsive enhancer binding protein (TonEBP). We used an MDCK cell line stably transfected with SMIT2 to determine whether variations in external osmolarity could also affect SMIT2 function. Hyperosmotic conditions (+200 mosM raffinose or NaCl but not urea) generated an increase in SMIT2-specific MI uptake by three- to ninefold in a process that required protein synthesis. Using quantitative RT-PCR, we have determined that hyperosmotic conditions augment both the endogenous SMIT1 and the transfected SMIT2 mRNAs. Transport activities for both SMIT1 and SMIT2 exhibited differences in their respective induction profiles for both their sensitivities to raffinose, as well as in their time course of induction. Application of MG-132, which inhibits nuclear translocation of TonEBP, showed that the effect of osmolarity on transfected SMIT2 was unrelated to TonEBP, unlike the effect observed with SMIT1. Inhibition studies involving the hyperosmolarity-related MAPK suggested that p38 and JNK play a role in the induction of SMIT2. Further studies have shown that hyperosmolarity also upregulates another transfected transporter (Na(+)-glucose), as well as several endogenously expressed transport systems. This study shows that hyperosmolarity can stimulate transport in a TonEBP-independent manner by increasing the amount of mRNA derived from an exogenous DNA segment.
authors.affiliation: Groupe d'étude des protéines membranaires, University de Montreal, Montreal, Quebec, Canada.
authors.forename: Pierre
authors.initials: P
authors.lastname: Bissonnette
authors.forename: Karim
authors.initials: K
authors.lastname: Lahjouji
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Coady
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Lapointe
mesh_terms: D000818:Animals; D002460:Cell Line; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D004285:Dogs; D006982:Hypertonic Solutions / Q000378:metabolism; D007295:Inositol Phosphates / Q000378:metabolism*; D048031:JNK Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D007700:Kinetics; D050778:NFATC Transcription Factors / Q000037:antagonists & inhibitors / Q000378:metabolism; D009997:Osmotic Pressure; D020033:Protein Isoforms; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D011887:Raffinose / Q000378:metabolism; D012462:Saline Solution, Hypertonic / Q000378:metabolism; D012964:Sodium / Q000378:metabolism*; D027981:Symporters / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D014162:Transfection; D015854:Up-Regulation; D014508:Urea / Q000378:metabolism; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D015853:Cysteine Proteinase Inhibitors; D006982:Hypertonic Solutions; D007295:Inositol Phosphates; D050778:NFATC Transcription Factors; D020033:Protein Isoforms; D047428:Protein Kinase Inhibitors; D012333:RNA, Messenger; D012462:Saline Solution, Hypertonic; D027981:Symporters; D014508:Urea; D012964:Sodium; D048031:JNK Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases; D011887:Raffinose